EBioMedicine · 2026
Prognostic value of microRNA expression in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ulmann Lőrinc, Obeidat Mahmoud, Bunduc Stefania, Váncsa Szilárd, Szentes Boglárka Lilla, Saleh Maryam, Baksay Maya, Dohán Orsolya, Hegyi Péter, Szücs Ákos
Аннотация
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) ranks among the deadliest malignancies, with limited survival benefits despite recent therapeutic advances. Few prognostic biomarkers are available for PDAC monitoring in clinical practice. We conducted a meta-analysis to evaluate and synthesise evidence on the prognostic significance of miRNA expression in PDAC.
METHODS: The protocol was registered with PROSPERO (CRD42023463542). We conducted a systematic search in PubMed, CENTRAL, and Embase on January 27, 2026, to identify studies assessing miRNA expression levels in patients with PDAC with reported overall survival (OS) or progression-free survival (PFS) outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using a random-effects model. Prediction intervals (PI) were reported if feasible. Separate analyses were performed by miRNA functional categories: oncogenic, tumour suppressor, chemoresistance-related, metastasis-related, and dual-role miRNAs.
FINDINGS: A total of 142 studies, including 13,824 patients, were included. High expression of oncogenic miRNAs was associated with worse univariate OS (HR 1.70, 95% CI 1.38-2.10; 95% PI 0.63-4.57) and PFS (HR 2.25, 95% CI 1.63-3.10; 95% PI 1.11-4.55). High expression of chemoresistance-related miRNAs was associated with worse multivariate OS (HR 2.11, 95% CI 1.68-2.66; 95% PI 0.96-4.68) and PFS (HR 2.51, 95% CI 1.89-3.33; 95% PI 1.58-3.97). Between-study heterogeneity varied substantially across pooled analyses (I2 range 0-94%). miRNA-21 was the most frequently studied individual biomarker and showed a consistent association with worse multivariate OS (HR 2.24, 95% CI 1.95-2.57; 95% PI 1.92-2.61).
INTERPRETATION: Elevated expression of oncogenic and chemoresistance-related miRNAs is associated with worse survival outcomes in PDAC. However, substantial heterogeneity and wide prediction intervals observed in several pooled analyses indicate variability in effect sizes across studies. Among the investigated biomarkers, miRNA-21 has shown the most consistent prognostic association and may represent the strongest candidate for future clinical implementation. Further validation and standardisation are required before miRNA profiling can be integrated into routine clinical practice.
FUNDING: None to declare.
METHODS: The protocol was registered with PROSPERO (CRD42023463542). We conducted a systematic search in PubMed, CENTRAL, and Embase on January 27, 2026, to identify studies assessing miRNA expression levels in patients with PDAC with reported overall survival (OS) or progression-free survival (PFS) outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using a random-effects model. Prediction intervals (PI) were reported if feasible. Separate analyses were performed by miRNA functional categories: oncogenic, tumour suppressor, chemoresistance-related, metastasis-related, and dual-role miRNAs.
FINDINGS: A total of 142 studies, including 13,824 patients, were included. High expression of oncogenic miRNAs was associated with worse univariate OS (HR 1.70, 95% CI 1.38-2.10; 95% PI 0.63-4.57) and PFS (HR 2.25, 95% CI 1.63-3.10; 95% PI 1.11-4.55). High expression of chemoresistance-related miRNAs was associated with worse multivariate OS (HR 2.11, 95% CI 1.68-2.66; 95% PI 0.96-4.68) and PFS (HR 2.51, 95% CI 1.89-3.33; 95% PI 1.58-3.97). Between-study heterogeneity varied substantially across pooled analyses (I2 range 0-94%). miRNA-21 was the most frequently studied individual biomarker and showed a consistent association with worse multivariate OS (HR 2.24, 95% CI 1.95-2.57; 95% PI 1.92-2.61).
INTERPRETATION: Elevated expression of oncogenic and chemoresistance-related miRNAs is associated with worse survival outcomes in PDAC. However, substantial heterogeneity and wide prediction intervals observed in several pooled analyses indicate variability in effect sizes across studies. Among the investigated biomarkers, miRNA-21 has shown the most consistent prognostic association and may represent the strongest candidate for future clinical implementation. Further validation and standardisation are required before miRNA profiling can be integrated into routine clinical practice.
FUNDING: None to declare.